Vaestra Goetalandsregionen
- Address
- lock Available on a paid plan
Psychiatry and Psychology: Behavioral Disciplines and Activities
At Vastraa Goetalandsregionen, the Dep of Pediatrics is contributing to clinical research in Psychiatry and Psychology with a focus on behavioral disciplines and related mental health conditions in children, adolescents, and adults. The studies are centered on evaluating new or existing treatments and understanding their effects on symptoms and day-to-day functioning.
- Research in ADHD is examining the safety and effectiveness of treatment options for children and adolescents who cannot use stimulant medicines.
- One key goal is to better understand how therapy may support attention, psychomotor speed, and overall cognitive performance.
- The site is also involved in work on schizophrenia spectrum disorder, looking at whether an immune-based treatment can improve psychiatric symptoms.
This area of research reflects a strong interest in improving care for mental disorders through studies that assess treatment benefit, symptom change, and longer-term patient outcomes.
Mental Disorders: ADHD and Schizophrenia Spectrum Disorder
The clinical trials at this hospital/clinic in Goteborg are focused on two major mental health conditions: attention-deficit/hyperactivity disorder and schizophrenia spectrum disorder. The research aims to compare treatment options, monitor safety, and explore whether therapies can improve everyday functioning and clinical symptoms.
- In ADHD, the trials are testing treatment effectiveness and long-term safety in younger patients.
- In schizophrenia spectrum disorder, the studies are evaluating whether a targeted therapy may reduce psychotic symptoms more effectively than placebo.
- These projects support better treatment selection for patients with complex psychiatric needs.
Overall, the research combines psychiatric care and clinical evaluation to help determine which approaches may offer the greatest benefit for patients.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1Vaestra Goetalandsregionen1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 188 other sites in Sweden
Therapeutic Area Benchmark — Sweden
Select a therapeutic area to compare against other sites in Sweden.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Sweden
Market Share
Country: Sweden
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Vaestra Goetalandsregionen
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 4, Multicenter, 2-part Study Composed of a Randomized, Double-blind, Parallel-group, Placebo-controlled, Active-comparator, Dose-optimization Evaluation followed by a Open-label Evaluation to Assess the Safety and Efficacy of Guanfacine Hydrochloride Prolonged-release (SPD503) in Children and Adolescents aged 6 to 17 Years with Attention-deficit/Hyperactivity Disorder | Takeda Development Center Americas Inc. | Phase III | Not Recruiting | Nov 2019 | Sep 2025 |
IMP list
lock Showing 1 of 6 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Atomoxetine Hydrochloride | 1 | Unknown | 2019-11-20 | 2019-11-20 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.
